Results 81 to 90 of about 20,522 (204)
The effect of ezetimibe on NAFLD
NAFLD has become the most common liver disorder in countries, where obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome are common. The strong association between these conditions and the risk of cardiovascular disease make treatment ...
AVERNA, Maurizio
core +1 more source
ABSTRACT Aims Large‐scale clinical trials have shown multiple effects of glucagon‐like peptide 1 receptor agonists (GLP‐1RAs); however, similar evidence for Asian patients is limited. Therefore, using a Japanese large‐scale claims‐based database, the effects of GLP‐1RAs on cardiovascular and cerebrovascular events including mortality were compared with
Masaya Koshizaka +7 more
wiley +1 more source
Ezetimibe therapy: mechanism of action and clinical update
Binh An P Phan,1 Thomas D Dayspring,2 Peter P Toth31Division of Cardiology, Loyola University Medical Center, Maywood, IL, USA; 2Foundation for Health Improvement and Technology, Wayne, NJ, USA; 3CGH Medical Center, Sterling, IL, USAAbstract: The ...
Toth PP, Dayspring TD, Phan BAP
core
Ezetimibe Blocks Internalization of the NPC1L1/Cholesterol Complex
Niemann-Pick C1-like 1 (NPC1L1) is a target for ezetimibe, a drug that blocks intestinal cholesterol absorption. A new study by Ge et al. (2008) in this issue of Cell Metabolism shows that non-lipoprotein-bound cholesterol induces endocytosis of NPC1L1 ...
Chang, Ta-Yuan, Chang, Catherine
core +1 more source
Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II) [PDF]
The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab has been shown to substantially reduce low-density lipoprotein cholesterol (LDL-C).
Mahfouz El Shahawy +17 more
core +1 more source
Lipoprotein(a), Endothelial Dysfunction and Cardiovascular Disease
ABSTRACT Lipoprotein(a) (Lp(a)) is a particle similar to low‐density lipoprotein cholesterol and is associated with apolipoprotein (A). High Lp(a) levels are a genetic, independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Endothelial cells, which form the continuous lining of the cardiovascular system, are crucial for vascular ...
Xianghui Zhou +5 more
wiley +1 more source
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara +9 more
wiley +1 more source
Combination therapy in cholesterol reduction: focus on ezetimibe and statins
Liliana Grigore1, Giuseppe Danilo Norata1,2, Alberico L Catapano1,21Department of Pharmacological Sciences, University of Milan, Milan, Italy; 2Center for the Study of Atherosclerosis, Bassini Hospital, Cinisello B, ItalyAbstract: Although widely used in
Liliana Grigore +5 more
core
Combined Effects of Ezetimibe and Phytosterols on Cholesterol Metabolism
Background— Both ezetimibe and phytosterols inhibit cholesterol absorption. We tested the hypothesis that the combination of ezetimibe and phytosterols is more effective than ezetimibe alone in altering cholesterol metabolism.
Xiaobo Lin +6 more
core +1 more source
Ezetimibe Alone Reduces Low‐Density Lipoprotein Cholesterol in HIV‐Infected Patients Receiving Combination Antiretroviral Therapy [PDF]
In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with human immunodeficiency virus infection, the mean changes in low-density lipoprotein cholesterol were -5.3% (-11 mg/dL) and + 5.5% (+ 4 mg/ dL) with ezetimibe ...
Napravnik, Sonia +8 more
core +1 more source

